BioMarin Sees $1.50 Q3 EPS Hit From Alesta Costs Ahead of Results

Your call?🐂 Bullish🐻 Bearish

The preliminary estimate includes $283 million in pretax acquired research and development expense. BioMarin plans to update its 2026 outlook when it discusses results Monday, Nov. 2.